MarginsXMarginsX
Home › Markets › Health Care › TEVA

Teva Pharmaceutical Industries Limited (TEVA)

TEVA trades on NYSE in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.

Price · November 16, 2026
$42.57
-4.34% on the day
Market cap
$49.7B
Large cap
Revenue · 2025
$17.3B
+4.3% on 2024
Net income · 2025
$1.4B
8.2% net margin

Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/818686/000119312526034532/0001193125-26-034532-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.

Profile

FieldValue
TickerTEVA on NYSE
SectorHealth Care
IndustryBiotechnology: Pharmaceutical Preparations
CountryIsrael
IPO yearNot reported by the screener
SEC CIK0000818686
SEC industry codePharmaceutical Preparations
Incorporated inIsrael

Financials · 2025

LineValue
Revenue$17.3B
Net income$1.4B
Operating income$2.2B
Net margin8.2%
Operating margin12.5%
Revenue growth+4.3%
Cash$3.6B
Total assets$40.7B
P/E (computed)35.2×
P/S (computed)2.9×

Warning signs

Cash runway
Cash-flow positive
$4.1B cash at September 30, 2026
Share count, 1 year
+1.7%
2025-09-30 to 2026-09-30 · +4.1% over 3 years
Going-concern doubt
No
10-Q filed November 3, 2026
Insider net buying, 12 months
-$112.7M
Through September 30, 2026
SignFindingSource
Going concernNo going-concern finding.10-Q 2026-11-03
Cash and burn$4.1B cash; operating cash flow $442.5M a quarter.Report 2026-09-30
Shares outstanding1,166,826,784 (2026-09-30); 1,147,282,512 a year earlier; 1,120,971,202 three years earlier.Cover page 2026-09-30
Reverse splits, 3 yearsNone foundNone on EDGAR
Shelf and offerings, 12 months0 S-3/F-3 shelf filings; 2 424B5 takedownsLatest 2026-09-11
Exchange deficiency notices, 12 monthsNoneNone on EDGAR
Delisting25-NSE filed25-NSE 2026-09-14
AuditorKesselman & Kesselman C.P.A.s, Tel-Aviv, IsraelPCAOB Form AP 2026-02-24
Late filings, 12 monthsNoneNone on EDGAR
Insider trades, 12 monthsBought $0, sold $112.7M on the open marketSEC Forms 3/4/5 data sets 2026-09-30

From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.

Quarterly results

QuarterRevenueNet incomeOp. cash flowCashTotal debtTTM revenueSource
Q3 2026
2026-09-30
$4.4B$233.0M$241.0M$4.1B$4.0B$14.0B10-Q 2026-11-03
Q2 2026
2026-06-30
$4.1B-$576.0M$411.0M$3.7B$4.5B$14.1B10-Q 2026-07-29
Q1 2026
2026-03-31
$4.0B$369.0M-$40.0M$3.7B$2.6B$14.1B10-Q 2026-04-29
Q4 2025
2025-12-31
$1.5B$480.0M$1.2B$3.6B$1.8B$14.0B10-K 2026-02-03
Q3 2025
2025-09-30
$4.5B$433.0M$369.0M$2.2B$1.0M$16.8B10-Q 2026-11-03
Q2 2025
2025-06-30
$4.2B$282.0M$227.0M$2.2B$441.0M$16.6B10-Q 2026-07-29
Q1 2025
2025-03-31
$3.9B$214.0M-$105.0M$1.7B$398.0M$16.6B10-Q 2026-04-29
Q4 2024
2024-12-31
$4.2B-$217.0M$575.0M$3.3B$1.8B$16.5B10-K 2026-02-03

From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).

Key SEC documents

DocumentFormFiled
Latest prospectus or offering document424B52026-09-11
Latest annual report10-K2026-02-03
Latest quarterly / interim10-Q2026-11-03
Latest current report
FORM 8-K
8-K2026-11-03
Latest proxyDEFA14A2026-03-31

Source: SEC EDGAR submissions feed, 1,001 recent filings. All filings on EDGAR.

Price moves

WindowReturn
1 week+4.4%
1 month+7.9%
3 months+21.9%
Year to date+42.6%
1 year+74.2%
From 52-week high0.0%

Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.

Peers in Biotechnology: Pharmaceutical Preparations

TickerCompanyPriceDayMarket cap
ONCBeOne Medicines Ltd.$411.29-1.26%$47.0B
RPRXRoyalty Pharma plc Class A Ordinary Shares$68.53-1.13%$39.3B
TAKTakeda Pharmaceutical Company Limited$21.59+0.75%$68.2B
ZTSZoetis Inc.$84.39+0.68%$34.3B
GMABGenmab A/S ADS$51.57+0.39%$32.2B
ROIVRoivant Sciences Ltd. Common Shares$38.61-2.33%$28.0B
INSMInsmed Incorporated$122.88+1.42%$27.0B
REGNRegeneron Pharmaceuticals Inc.$952.40-0.32%$98.5B

The full dossier has every filing, three years of financials, private raises and the people who signed them.

Open the full dossier